What is a Technologies to Tools award?
The Technologies to Tools (T2T) awards support the translation of non-animal in vitro models and technologies, developed with NC3Rs grant funding, into research tools that can be applied confidently in the pharmaceutical industry to support improved medicines discovery. The aim is to bridge the gap between model development and the wider uptake needed to achieve the greatest 3Rs, scientific and commercial impacts.
These awards are being offered in collaboration with the Medicines Discovery Catapult (MDC). Eligible researchers will have the opportunity to develop a collaborative project with MDC which builds upon the scientific findings arising from their NC3Rs grant. Applicants can apply for up to £50k, to cover 100% of their directly incurred costs, for projects of up to 24 months duration. The MDC will provide in-kind contributions (for example, access to industrial expertise, facilities and equipment), equivalent in value to the funding offered by the NC3Rs.
Please note that this scheme will not be running in 2020.
Key information on the application process is given below. Applicants should read the Applicant Guidance, which contains more detailed information about the application process.
Who can apply | How to apply | Assessment procedure | Related documents
Who can apply?
Establishment eligibility |
Any UK research establishment including:
Note: Awards made under this scheme constitute de minimis aid. Any one organisation cannot be provided with more than the de minimis funding threshold of €200k over a three-year fiscal period. |
Individual eligibility |
Applicants must be UK-based researchers who can demonstrate that they:
Applicants must:
|
Overseas researchers
Overseas researchers cannot be Primary Investigators but can be included as collaborators. Overseas co-applicant status can be obtained in exceptional circumstances at the discretion of the NC3Rs; approval must be sought before applying.
Resubmissions
The NC3Rs does not allow resubmission of previously unsuccessful proposals, unless explicitly invited by the Panel. Proposals previously declined by the NC3Rs will not be considered by another Research Council or funder within 12 months (from the date of submission to the original Research Council) unless substantially revised. More information can be found in the NC3Rs Applicant and Grant Holder Handbook.
Please note: The same or similar application cannot be considered by any other Research Council, the Health Departments or any other research funder at the same time
How to apply
Prospective applicants are required to present the outcomes of the NC3Rs grant, upon which an application would be based, to the MDC at a Research Showcase event organised by the NC3Rs.The MDC will then select projects that fall within their remit and to which their expertise can add value and work with the research team to develop a collaborative application for submission to the T2T competition.
MDC criteria for selecting projects |
---|
|
Applications must be made using the application form.
Completed applications must be sent by email to 3rsgrants@nc3rs.org.uk. All applications are treated in confidence.
General guidance
- Application forms and attachments must be submitted as PDF files.
- Failure to complete mandatory fields on the application form and to submit all required attachments may result in the application being rejected.
- The application form should be completed using a font size no smaller than 10pt (Arial) and text limits must not be exceeded.
- The use of acronyms should be kept to a minimum.
Assessment procedure
Proposals are assessed by the NC3Rs Technologies to Tools Assessment Panel.
Member | Institution | Term ends |
Dr Ian Ragan | Independent | 2019 |
Dr Jamie Bilsland | C4X Discovery Ltd | 2019 |
Dr Lorna Ewart | AstraZeneca | 2019 |
Professor Christopher George | Swansea University | 2019 |
Dr Diane Harbison | Decipher Analytics Ltd | 2019 |
Dr Mark Holbrook | VAST pharma solutions Ltd and Certara Ltd | 2019 |
Dr John Kendrick | Covance Ltd | 2019 |
Dr Nicola Valeri | The Institute of Cancer Research | 2019 |
Dr Debbie Taylor | LifeArc | 2019 |
The following criteria are taken into consideration by the Panel when making the funding decisions:
Panel Assessment criteria |
---|
|
In order to maintain the transparency and integrity of the peer review process we have adopted the MRC policy on peer review.
Please note the T2T Panel assessment guidance and scoring criteria below.
Related documents
Application process
Assessment criteria
Award agreement template